Author: ["Angela Nebbioso","Nicole Clarke","Emilie Voltz","Emmanuelle Germain","Concetta Ambrosino","Paola Bontempo","Rosana Alvarez","Ettore M Schiavone","Felicetto Ferrara","Francesco Bresciani","Alessandro Weisz","Angel R de Lera","Hinrich Gronemeyer","Lucia Altucci"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Chromatin is a dynamic macromolecular structure epigenetically modified to regulate specific gene expression. Altered chromatin function can lead to aberrant expression of growth regulators and may, ultimately, cause cancer. That many human diseases have epigenetic etiology has stimulated the development of 'epigenetic' therapies. Inhibitors of histone deacetylases (HDACIs) induce proliferation arrest, maturation and apoptosis of cancer cells, but not normal cells, in vitro and in vivo, and are currently being tested in clinical trials1,2,3,4,5. We investigated the mechanism(s) underlying this tumor selectivity. We report that HDACIs induce, in addition to p21, expression of TRAIL (Apo2L, TNFSF10) by directly activating the TNFSF10 promoter, thereby triggering tumor-selective death signaling in acute myeloid leukemia (AML) cells and the blasts of individuals with AML. RNA interference revealed that the induction of p21, TRAIL and differentiation are separable activities of HDACIs. HDACIs induced proliferation arrest, TRAIL-mediated apoptosis and suppression of AML blast clonogenicity irrespective of French-American-British (FAB) classification status, karyotype and immunophenotype. No apoptosis was seen in normal CD34+ progenitor cells. Our results identify TRAIL as a mediator of the anticancer action of HDACIs.Cite this article
Nebbioso, A., Clarke, N., Voltz, E. et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11, 77–84 (2005). https://doi.org/10.1038/nm1161 